220513-46-2

Usage

Uses

Used in Pharmaceutical Research:
6-Bromo-8-fluoroquinoline is used as a precursor in the synthesis of various bioactive molecules, particularly for the development of antiviral and antibacterial agents. Its unique structure and pharmacological properties make it a promising candidate for the creation of new therapeutic agents.
Used in Organic Synthesis:
As a key intermediate in organic synthesis, 6-Bromo-8-fluoroquinoline is utilized to construct complex organic molecules with potential applications in various fields, including pharmaceuticals, agrochemicals, and materials science.
Used in Biomedical Imaging:
6-Bromo-8-fluoroquinoline is used as a fluorescent probe and dye in biomedical imaging applications. Its fluorescent properties allow for the visualization and tracking of biological processes, making it a valuable tool in research and diagnostics.

Upstream product

• 367-24-8 4-bromo-2-fluoroaniline 
• 56-81-5 glycerol 
• 107-02-8 acrolein 
• 127-68-4 sodium 3-nitrobenzenesulfonate 

Downstream Products

• 1241745-68-5 8-fluoro-6-(phenylmethyl)quinoline 
• 1061650-25-6 8-fluoroquinoline-6-carboxylic acid 
• 1210048-29-5 (8-fluoroquinolin-6-yl)boronic acid 

Relevant academic research and scientific papers

UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS

The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.

HETEROCYCLIC COMPOUNDS

The present invention relates to compounds of the general formula (1) wherein the variables are defined as given in the description and claims. The invention further relates to uses of and to, processes and intermediates related to compounds of the general formula (I), wherein Q is wherein the substituents of I, Ia and Ib are as defined in description and claims.

Quinoline compounds and preparation method thereof, and intermediate, pharmaceutical composition and application of quinoline compounds

The invention discloses quinoline compounds and a preparation method thereof, and an intermediate, a pharmaceutical composition and application of quinoline compounds. The invention provides quinoline compounds disclosed as Formula 1, and pharmaceutically acceptable salts, solvates, metabolites, metabolism precursors or pharmaceutical precursors thereof. The quinoline compounds have favorable inhibitory effects on tyrosine kinase C-Met, and can be used for preparing drugs for prevention, treatment or auxiliary treatment on multiple diseases related to C-Met expression or activity, and especially neoplastic diseases.

QU1NOLINE DERIVATIVES AND THEIR USES FOR RHINITIS AND URTICARIA

The present invention relates to compounds of formula (I) and salts thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various diseases, such as allergic rhinitis.

SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF

The present application relates to novel substituted 5-aminopyrazoles, methods of production thereof, use thereof alone or in combinations for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases.

The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists

As part of an effort to identify 5-HT1A antagonists that did not possess typical arylalkylamine or keto/amido-alkyl aryl piperazine scaffolds, prototype compound 10a was identified from earlier work in a combined 5-HT 1A antagonist/SSRI program. This quinolyl-piperazinyl piperidine analogue displayed potent, selective 5-HT1A antagonism but suffered from poor oxidative metabolic stability, resulting in low exposure following oral administration. SAR studies, driven primarily by in vitro liver microsomal stability assessment, identified compound 10b, which displayed improved oral bioavailability and lower intrinsic clearance. Further changes to the scaffold (e.g., 10r) resulted in a loss in potency. Compound 10b displayed cognitive enhancing effects in a number of animal models of learning and memory, enhanced the antidepressant-like effects of the SSRI fluoxetine, and reversed the sexual dysfunction induced by chronic fluoxetine treatment.

QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES

The present invention relates to compounds of formula (I) and salts thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various diseases, such as allergic rhinitis.